Tolerability Concerns for GLP-1/Glucagon Agonist in Obesity, MASLD

(MedPage Today) -- NEW ORLEANS--Treatment with survodutide led to significant weight loss and reductions in liver fat in phase III trials of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), but about a fifth of...